Wegovy is an injectable medication containing semaglutide, a GLP-1 receptor agonist
Though, most people lose significant weight after 6 months, with more to come over the next 12 months
Digital Behavioral Change: The Missing Piece: While medical interventions like medications and surgeries play crucial roles in managing obesity and diabetes, they often fall short of addressing the root causes of these conditions
Most eligible patients still aren't receiving GLP-1 medications Even as GLP-1 trends climb, most people diagnosed with overweight or obesity are not receiving prescriptions
Be ActiveEven Small Steps Count Exercise enhances weight loss and helps preserve muscle while burning fat
Qureshi-Baig K, Ullmann P, Haan S, Letellier E